Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPV Priming and Antibody Decay With or Without bOPV
NCT03202719Phase 4Completed
- Sponsor
- Centers for Disease Control and Prevention
- Start
- Nov 2017
- Primary completion
- Oct 2019
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of trivalent inactivated polio vaccine in poliomyelitis (5 arms), sponsored by Centers for Disease Control and Prevention. Primary endpoints: Immunogenicity of IPV vaccination schedule at 18 months and Poliovirus type 2 priming with IPV. Started Nov 2017; status: completed.
02
Drugs
trivalent inactivated polio vaccine
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT03202719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03202719.